BioXcel Therapeutics, Inc. (BTAI) Ownership
BTAI ownership summary
as of September 13, 2026- Institutions
- 10.3% of shares outstanding
- Insiders
- 0.00% of shares outstanding
- Shares outstanding
- 31.3M
- Float
- 26.9M shares available to trade
- Short interest
- 10.78% 3.3M shares short
- Days to cover
- 4.02 short interest down 21.4% vs prior month
- Institutions 10.28%
- Other investors 89.72%
BTAI top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Millennium Management LLC | 6.76% | 2.1M | $101,295 | +177,950 (+9.2%) | June 30, 2026 |
| 2 | Armistice Capital, LLC | 6.10% | 1.9M | $91,493 | +1.9M (0.0%) | March 31, 2026 |
| 3 | Oaktree Capital Management LLC | 0.77% | 241K | $11,553 | — | March 31, 2026 |
| 4 | Geode Capital Management, LLC | 0.74% | 230K | $11,025 | +24,000 (+11.6%) | March 31, 2026 |
| 5 | Vanguard Capital Management, LLC | 0.66% | 207K | $9,932 | +207,339 (0.0%) | March 31, 2026 |
| 6 | Citadel Advisors Llc | 0.48% | 149K | $7,148 | +149,220 (0.0%) | June 30, 2026 |
| 7 | JONES FINANCIAL COMPANIES LLLP | 0.42% | 132K | $6,313 | −5,901 (−4.3%) | March 31, 2026 |
| 8 | Man Group PLC | 0.31% | 96K | $4,621 | +39,648 (+69.8%) | March 31, 2026 |
| 9 | State Street Corp | 0.29% | 92K | $4,412 | +28,900 (+45.7%) | March 31, 2026 |
| 10 | FMR Inc | 0.29% | 90K | $4,325 | — | March 31, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 0.27% | 85K | $4,068 | +84,921 (0.0%) | March 31, 2026 |
| 12 | BlackRock Inc | 0.27% | 84K | $4,037 | −114 (−0.1%) | March 31, 2026 |
| 13 | Wiley Bros.-Aintree Capital, LLC | 0.26% | 81K | $3,873 | +80,864 (0.0%) | March 31, 2026 |
| 14 | UBS Group AG | 0.17% | 53K | $2,529 | +14,448 (+37.7%) | March 31, 2026 |
| 15 | Oaktree Fund Advisors, LLC | 0.14% | 43K | $2,056 | — | March 31, 2026 |
| 16 | HighTower Advisors, LLC | 0.13% | 41K | $1,964 | — | March 31, 2026 |
| 17 | Quadrature Capital Limited | 0.12% | 38K | $1,822 | +38,038 (0.0%) | June 30, 2026 |
| 18 | Northern Trust Corp | 0.12% | 36K | $1,739 | −2,057 (−5.4%) | March 31, 2026 |
| 19 | Beacon Pointe Advisors, LLC | 0.06% | 19K | $904 | +18,877 (0.0%) | March 31, 2026 |
| 20 | Portfolio Strategies, Inc. | 0.05% | 17K | $806 | +4,653 (+38.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 2.8M shares and 3 cut 8,072.
BTAI top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.17% | 680K | $32,551 | — | July 31, 2026 |
| 2 | Vanguard Institutional Extnd Mkt Idx Tr | 0.77% | 240K | $11,495 | — | July 31, 2026 |
| 3 | Fidelity Extended Market Index | 0.40% | 126K | $6,027 | −235 (−0.2%) | July 31, 2026 |
| 4 | Fidelity Select Biotechnology | 0.29% | 90K | $4,325 | — | July 31, 2026 |
| 5 | iShares Micro-Cap ETF | 0.28% | 89K | $4,245 | −1,761 (−1.9%) | August 31, 2026 |
| 6 | Blackrock Extended Mkt Fund CF | 0.22% | 69K | $3,320 | — | May 31, 2026 |
| 7 | Extended Equity Market Fund B | 0.22% | 69K | $3,320 | — | December 31, 2025 |
| 8 | Extended Equity Market Fund E | 0.22% | 69K | $3,320 | — | December 31, 2025 |
| 9 | BlackRock Extended Equity Market Fund K | 0.19% | 59K | $2,822 | −108 (−0.2%) | June 30, 2026 |
| 10 | Fidelity Total Market Index | 0.11% | 34K | $1,640 | — | July 31, 2026 |
| 11 | NT Ext Equity Mkt Index Fund - Lending | 0.10% | 31K | $1,500 | +17,884 (+133.1%) | June 30, 2026 |
| 12 | Northern Trust Extended Eq Market Idx | 0.10% | 31K | $1,500 | +17,884 (+133.1%) | June 30, 2026 |
| 13 | Fidelity Series Total Market Index | 0.09% | 30K | $1,415 | — | July 31, 2026 |
| 14 | Spartan Extended Market Index Pool F | 0.08% | 26K | $1,235 | +235 (+0.9%) | July 31, 2026 |
| 15 | NT Ext Equity Mkt Index Fund - NL | 0.08% | 24K | $1,162 | +2,121 (+9.6%) | June 30, 2026 |
| 16 | Oaktree Diversified Income Fund Inc D | 0.07% | 20K | $975 | +16,797 (+472.2%) | June 30, 2026 |
| 17 | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 0.06% | 18K | $843 | +254 (+1.5%) | June 30, 2026 |
| 18 | Spartan Total Market Index Pool A1 | 0.05% | 15K | $739 | — | July 31, 2026 |
| 19 | Oaktree Strategic Credit I | 0.04% | 13K | $608 | +187 (+1.5%) | March 31, 2026 |
| 20 | Fidelity Nasdaq Composite Index | 0.03% | 11K | $521 | — | July 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
BTAI insider transactions
latest 18| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2024-12-16 | Vimal Mehta | Sell | $5.76 | 194 | $1,117 |
| 2024-12-16 | Vincent O'neill | Sell | $5.60 | 10 | $56 |
| 2024-12-16 | Richard I Steinhart | Sell | $5.76 | 36 | $207 |
| 2024-10-03 | Matthew T Wiley | Sell | $8.80 | 392 | $3,450 |
| 2024-10-03 | Richard I Steinhart | Sell | $8.80 | 448 | $3,942 |
| 2024-09-16 | Frank Yocca | Sell | $11.04 | 22 | $243 |
| 2024-09-16 | Richard I Steinhart | Sell | $11.04 | 22 | $243 |
| 2024-09-16 | Vimal Mehta | Sell | $11.04 | 123 | $1,358 |
| 2024-06-17 | Vimal Mehta | Sell | $20.48 | 133 | $2,724 |
| 2024-06-17 | Frank Yocca | Sell | $20.48 | 23 | $471 |
| 2024-06-04 | Vimal Mehta | Sell | $26.08 | 7,875 | $205,380 |
| 2024-04-04 | Richard I Steinhart | Sell | $42.08 | 66 | $2,777 |
| 2024-04-04 | Vimal Mehta | Sell | $41.92 | 329 | $13,792 |
| 2024-04-04 | Vincent O'neill | Sell | $41.92 | 10 | $419 |
| 2023-06-15 | Vimal Mehta | Sell | $344.64 | 1,875 | $646,200 |
| 2023-05-22 | Vimal Mehta | Sell | $412.64 | 406 | $167,532 |
| 2023-05-15 | Javier Rodriguez | Sell | $437.12 | 111 | $48,520 |
| 2023-05-15 | Richard I Steinhart | Sell | $434.72 | 312 | $135,633 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
BTAI shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns BTAI
Institutional investors own 10.3% of BioXcel Therapeutics's shares and insiders 0.00%. The largest holder is Millennium Management LLC with 6.76% of the shares (2.1M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 3 reduced their stake in the latest filings. Short interest is 10.78% of the float, or 4.02 days of average trading volume. The share count rose 1,120.8% since 2016.
Related: BTAI analyst forecast, BTAI key metrics. See the BTAI stock overview for the latest quote and news.
BTAI ownership FAQ
Who owns the most BioXcel Therapeutics stock?
The largest shareholders of BioXcel Therapeutics are Millennium Management LLC (6.76%), Armistice Capital, LLC (6.10%), Oaktree Capital Management LLC (0.77%), Geode Capital Management, LLC (0.74%), Vanguard Capital Management, LLC (0.66%).
What percentage of BioXcel Therapeutics is owned by institutions?
Institutions hold 10.3% of BioXcel Therapeutics's shares outstanding; insiders hold 0.00%.
Which funds own BioXcel Therapeutics?
The largest fund holders of BioXcel Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.17%), Vanguard Institutional Extnd Mkt Idx Tr (0.77%), Fidelity Extended Market Index (0.40%), Fidelity Select Biotechnology (0.29%), iShares Micro-Cap ETF (0.28%).
What is BioXcel Therapeutics's short interest?
3.3M shares of BioXcel Therapeutics were sold short, 10.78% of the float; at the average daily volume it would take 4.02 days to cover.
Are insiders buying or selling BioXcel Therapeutics?
Of the latest 18 reported insider transactions in BioXcel Therapeutics (since May 15, 2023), 0 were purchases and 18 were sales.
How many shares of BioXcel Therapeutics are outstanding?
BioXcel Therapeutics has 31.3M shares outstanding, of which 26.9M are in the public float.